In an open‑label pilot of 16 medically hospitalised recent suicide attempters, a single intravenous ketamine infusion (0.5 mg/kg) produced rapid, large reductions in suicidality and depression at 24 hours and 5 days (Cohen’s d 1.7–8.8) that were sustained up to six months. The study indicates ketamine is a feasible, rapidly acting intervention for acute suicidality in real‑world Consultation‑Liaison settings.
- Published
- Journal
- International Journal of Environmental Research and Public Health
- Authors
- Shivanekar, S., Pizon, A., Spotts, C., Cruz, N., Lightfoot, M., Rohac, R., Baumeister, A., Griffo, A., Panny, B., Kucherer, S., Israel, A., Rengasamy, M., Price, R., Goplan, P.